Why semaglutide is at the center of MDL 3094
Semaglutide was the first widely prescribed GLP-1 weight-loss therapy. Its rapid adoption is now matched by a rapidly growing docket of injury claims, all consolidated in the Eastern District of Pennsylvania.
Qualifying injuries
Gastroparesis, severe pancreatitis, intestinal obstruction, gallbladder disease, vision loss (NAION), and aspiration pneumonia are the principal claims. New injury categories continue to be added as evidence develops.